DZD-8586 is under clinical development by Dizal Pharmaceutical and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DZD-8586’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DZD-8586 overview
DZD-8586 is under development for the treatment of non-hodgkin lymphoma, b-cell non-Hodgkin lymphoma, relapsed and refractory chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma, CNS Lymphoma, follicular lymphoma, marginal zone B-cell lymphoma. It is administered through oral route. It acts by targeting Bruton’s tyrosine kinase (BTK).
Dizal Pharmaceutical overview
Dizal Pharmaceutical (Dizal) is a biopharmaceutical company. It focuses on research, development, and commercialization of therapies to treat cancer and immunological diseases. The company’s lead product candidate ZEGFROVY, which is at marketing approval stage for treatment of solid tumors. Its product pipeline includes other drug programs such as JAUKPO to treat hematological malignancy, solid tumors, and immunological diseases; DZD8586 for treatment of hematological malignancy; and DZD2269 and DZD1516 to treat solid tumors. The company operates with additional facilities in Beijing, Wuxi, Chengdu, China. Dizal is headquartered in Shanghai, China.
For a complete picture of DZD-8586’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
